Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment



European Medicines Agency
News & Press Releases
News: Advancing international collaboration on COVID-19 real-world evidence and observational studies (new)
Last updated: 04/06/2021



News: EU regulators develop recommendations to forecast demand of medicines (new)
Last updated: 03/06/2021



News: Additional manufacturing capacity for BioNTech/Pfizer’s COVID-19 vaccine (new)
CHMP, Last updated: 01/06/2021
EMA has recommended the approval of additional manufacturing and filling lines at Pfizer’s vaccine manufacturing site in Puurs, Belgium. The recommendation by the Agency’s Committee for Human Medicines (CHMP) is expected to have a significant and immediate impact on the supply of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, in the European Union…



European Centre for Disease Prevention and Control
Latest Updates
Reducing COVID 19 transmission and strengthening vaccine uptake among migrant populations in the EU/EEA
Technical report – 3 Jun 2021

Suspected adverse reactions to COVID-19 vaccination and the safety of substances of human origin
Technical report – 3 Jun 2021

Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA
Technical report – 1 Jun 2021

ECDC report outlines considerations for COVID-19 vaccination of adolescents
News story – 1 Jun 2021



European Commission
Press release 4 June 2021
EU proposes a strong multilateral trade response to the COVID-19 pandemic
Today, the EU has submitted its proposal seeking the commitment of World Trade Organization (WTO) members for a multilateral trade action plan to expand the production of COVID-19 vaccines and treatments, and ensure universal and fair access.

Speech 2 June 2021
Speech by President von der Leyen at the Gavi COVAX Advance Market Commitment Summit
I am particularly grateful that the EU’s industrial partners have committed themselves too. They will make available 1.3 billion doses in 2021. BioNTech-Pfizer, Johnson & Johnson and Moderna will provide these vaccines at no profit for the low-income countries and at lower prices for the middle-income countries. And they will supply an additional 1 billion or more doses in 2022. It’s in our mutual interest to end this global pandemic as soon as possible.
That’s why the EU, together with the European Investment Bank, will reorient 300 million euros to COVAX. This is Team Europe’s contribution to AVATT, COVAX’s cost-sharing rapid finance scheme. This scheme will help vaccine purchases in Africa. And it will foster links between COVAX and the African Union.
You can continue to count on Team Europe’s commitment. We are here for the long haul. We are here until we end the pandemic everywhere.

Press release 1 June 2021
EU Digital COVID Certificate: EU Gateway goes live with seven countries one month ahead of deadline
Today, the EU Digital COVID Certificate has reached another important milestone with the go-live of the technical system at EU level, which allows to verify certificates in a secure and privacy-friendly way.